Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q4 FY13 Earnings Presentation
16 slides from Alembic Pharmaceuticals's earnings presentation, March 2013
Slide 1: Alembic Pharmaceuticals Limited Investors Update Q4 FY13
Alembic Pharmaceuticals Limited Investors Update Q4 FY13 www.alembic-india.com
Slide 2: Safe Harbour Statement
Safe Harbour Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diff
Slide 3: Financial Highlights – Q4 FY13
Financial Highlights – Q4 FY13 Financial & Operating Result Rs in lacs Particulars Q4 FY13 Q4 FY12 % Growth Income from Operations 37,808 34,234 10% Total Expenditure 31,250 30,149 - EBDITA 6,558 4,084 61% Other Income 7 40 - EBDITA including Other Income 6,565 4,125 59% Depreciation 864 892 - Inter
Slide 4: Financial Highlights – 2012-13
Financial Highlights – 2012-13 Financial & Operating Result Rs in lacs Particulars 2012-13 2011-12 % Growth Income from Operations 152,034 146,541 4% Total Expenditure 126,838 124,597 - EBDITA 25,196 21,943 15% Other Income 393 142 - EBDITA including Other Income 25,589 22,086 16% Depreciation 3,497
Slide 5: Financial Highlights – Q4 FY13 Total Revenue
Financial Highlights – Q4 FY13 Total Revenue Rs in lacs Particulars Q4 FY13 Q4 FY12 % Change Formulation Domestic 20,752 18,447 12% International Branded 1,286 1,774 -28% International Generics 7,766 5,037 54% API Domestic 2,501 1,921 30% International 5,366 6,814 -21% Export Incentives 165 237 Tota
Slide 6: Financial Highlights – 2012-13 Total Revenue
Financial Highlights – 2012-13 Total Revenue Rs in lacs Particulars 2012-13 2011-12 % Change Formulation Domestic 88,627 78,261 13% International Branded 4,412 5,670 -22% International Generics 23,577 24,180 -2% API Domestic 11,382 9,424 21% International 23,674 27,922 -15% Export Incentives 928 1,3
Slide 7: Highlights – Q4 / YTD FY13
Highlights – Q4 / YTD FY13 Net sales up 11% at Rs 378.36 crores against Rs. 342.30 crores in corresponding quarter last year Domestic formulations sales up by 12% for the quarter at Rs. 207.52 crores against Rs. 184.47 crores in corresponding quarter last year EBITDA at 17% of Rs. 65.58 crores
Slide 8: Business Update: Domestic Formulation Business
Business Update Domestic Formulation Business Domestic formulations sales up by 12% for the quarter at Rs. 207.52 crores against Rs. 184.47 crores in corresponding quarter last year. The industry growth rate has come down from 15-16% to 11% in reccent months. Growth of 31% in Specialty business
Slide 9: Business Update: Therapy wise performance – Q4 FY13
Business Update Domestic Formulation Business – Therapy wise performance – Q4 FY 13 March 2013 March 2012 Nephrology / Nephrology / Opthalmology Anti-Diabetics Urology Opthalmology Urology Anti-Diabetics 1% 4% 2% 1% 3% 4% Orthopedics Orthopedics 5% 5% Cardiology 9% Gynecology Anti Infectives Anti In
Slide 10: Business Update: Therapy wise performance YTD
Business Update Domestic Formulation Business – Therapy wise performance March YTD 2013 March YTD 2012 Therapy Market Alembic Therapy Market Alembic Therapy Growth Share Growth Growth Share Growth Gastrology 11 2.61 25 11 2.33 28 Cardiology 12 1.44 42 16 1.13 22 Anti Diabetic 23 1.33 40 25 1.18 26 G
Slide 11: Business Update: International Generics and API Business
Business Update International Generics Business International Generic Formulation Sales is Rs 77.66 crores as against Rs 50.37 crores in corresponding quarter last year representing healthy 54% growth Company partially commissioned its new Formulation facility. Company expects full plant to be o
Slide 12: Research and Development
Research and Development R & D expense for Q4 FY 13 is Rs 22.00 crores representing 5.0% of sales In the quarter 2 ANDA’s were filed, cumulative ANDA filings of the company at 57 3 ANDA approvals received in current quarter taking cumulative ANDA approvals to 24 Increased focus on Europe and
Slide 13: Research Capabilities
Research Capabilities 57 ANDA Filing ANDAs filed 60 with DMFs Filing DMFs filed 24 ANDA 60 57 54 approvals 44 45 37 32 26 25 18 18 11 18 13 13 12 11 9 8 7 7 7 6 6 Up to 2008-09 2009-10 2010-11 2011-12 2012-13 Up to 2008-09 2009-10 2010-11 2011-12 2012-13 2007-08 2007-08
Slide 14: Outlook Ahead
Outlook Ahead Company on robust growth path to attain: 30% CAGR in International Generics More than market growth in Domestic Formulation Business EBDITA growth of 20% p.a. on sustainable basis Strategy and Approach: Growing Chronic therapies through multiple marketing divisions and new prod
Slide 15: Conference Call Details
Conference Call Details Date : Friday, May 3, 2013 Time : 4.00 pm IST India - Primary Number +91 22 6629 0302 India - Secondary Number +91 22 3065 0102 USA 1 866 746 2133 UK 0 808 101 1573 Singapore Toll Free No. 800 101 2045 Hong Kong Toll Free No. 800 964 448
Slide 16: About Alembic Pharmaceuticals Limited
About Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharm
Alembic Pharmaceuticals — Q4 FY13 Earnings Presentation on 6ix